0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. "Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets," Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 28, 2026 04:23 ET (08:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.